Tiziana (TLSA) Announces Article on Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function, Induced T Cell Regulatory Response in Human Subjects

Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response i

Third-party research conducted by leading U.S. academic institutions published in a peer reviewed journal Frontiers in Immunology shows a favorable safety profile for intranasally administered foralumab and immunological activity in humans Finding supports Tizianas intranasal foralumab monoclonal antibody platform as a new modality for the treatment of autoimmune and CNS diseases

Tizianas fully human foralumab is the first anti-CD3 mAb which has not shown an anti-drug antibody (immune reaction) in humans

NEW YORK, Nov. 23, 2022 (GLOBE... More